共 25 条
[1]
Gregg E.W.(2005)Secular trends in cardiovascular disease risk factors according to body mass index in US adults JAMA 293 1868-1874
[2]
Cheng Y.J.(2007)Drug treatments for obesity: orlistat, sibutramine, and rimonabant Lancet 369 71-77
[3]
Cadwell B.L.(2007)Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study Circulation 115 1991-1998
[4]
Padwal R.S.(2001)Use of beta-blockers in obesity hypertension: potential role of weight gain Obes Rev 2 275-280
[5]
Majumdar S.R.(2007)Antihypertensive agents, insulin sensitivity, and new-onset diabetes Curr Diab Rep 7 191-199
[6]
Scholze J.(2007)ESH-ESC Task Force on the Management of Arterial Hypertension: 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension J Hypertens 25 1751-1762
[7]
Grimm E.(2007)Canadian Hypertension Education Program: the 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2—therapy Can J Cardiol 23 539-550
[8]
Herrmann D.(2004)Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study Int J Obes Relat Metab Disord 28 378-383
[9]
Pischon T.(2001)Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet-exercise intervention Int J Obes Relat Metab Disord 25 1144-1153
[10]
Sharma A.M.(undefined)undefined undefined undefined undefined-undefined